dupilumab

targets

all catalysts(33)

News(10)

• AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
  Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.
  biospace · 7d ago
• New data could widen use of AstraZeneca, Amgen immune disease drug
  Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
  biopharma_dive · 7d ago
• Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
  Having set Metsera on its journey to a $10 billion takeover, Arch Venture Partners and Population Health Partners have powered their new startup—Sentivera—to a licensing deal worth up to $1.5 billion.
  fiercebiotech · 10d ago
• Regeneron ends eye disease study due to antibody's safety profile
  The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
  biospace · 17d ago
• Regeneron ends eye disease study due to antibody's safety profile
  The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
  biospace · 17d ago
• Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
  Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.
  biopharma_dive · 24d ago
• Regeneron backs $75M series A for antibody upstart Infinimmune
  Infinimmune has amassed further fuel to power its antibody discovery engine, netting a $75 million series A headlined by Regeneron’s venture arm.
  fiercebiotech · 24d ago
• Braveheart pumps more life into biotech IPO market with $382M expected debut
  Braveheart Bio has emerged on the Nasdaq with an upsized expected initial public offering—marking the public entrance of the twenty-second biotech this year.
  biospace · 29d ago
• Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
  Since stepping in as Sanofi’s CEO in April, Belén Garijo has launched a deep look at the pharma’s pipeline, reassessing assets based on “scientific merit” and potential for long-term value in the q…
  biospace · 29d ago
• A COPD drug from China draws $115M in venture funding
  Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.
  biopharma_dive · 1mo ago